BridgeBio Pharma

- BBP-671 detected in healthy volunteer plasma and cerebrospinal fluid (CSF), suggesting that BBP-671 is entering the brain, a location critical to target neurological complications of PKAN…

-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million -Secured a two-year extension of…

- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties -SHP2 inhibitor…

- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from…

- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential…

- If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make…

- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation PALO ALTO, Calif., Jan. 13, 2022…

- ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters,…

- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs…